Key result
Experimental and pre-clinical evidence supports the potential use of IL-6 signaling blockade to prevent allograft rejection and improve outcomes in heart transplant recipients.
Why the study?
Outcomes after heart transplantation remain suboptimal, with acute and chronic rejection contributing to poor long-term survival, highlighting the need to evaluate IL-6 inhibition strategies.
Does IL-6 signaling blockade prevent allograft rejection in heart transplant recipients?
Does IL-6 signaling blockade prevent allograft rejection in heart transplant recipients?
IL-6 signaling blockade represents a promising therapeutic strategy to prevent acute and chronic allograft rejection following heart transplantation.
IL-6 blockade merits clinical trials in heart transplant recipients; leaves open whether it prevents rejection in humans.
Outcomes following heart transplantation remain suboptimal with acute and chronic rejection being major contributors to poor long-term survival. IL-6 is increasingly recognized as a critical pro-inflammatory cytokine involved in allograft injury and has been shown to play a key role in regulating the inflammatory and alloimmune responses following heart transplantation. Therapies that inhibit IL-6 signaling have emerged as promising strategies to prevent allograft rejection. Here, we review experimental and pre-clinical evidence that supports the potential use of IL-6 signaling blockade to improve outcomes in heart transplant recipients.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2022) conducted a review in Cardiac allograft rejection. IL-6 signaling blockade was evaluated. Experimental and pre-clinical evidence supports the potential use of IL-6 signaling blockade to prevent allograft rejection and improve outcomes in heart transplant recipients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: